X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs NOVARTIS - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON NOVARTIS BIOCON /
NOVARTIS
 
P/E (TTM) x 40.9 395.8 10.3% View Chart
P/BV x 7.1 31.7 22.4% View Chart
Dividend Yield % 0.2 1.4 11.3%  

Financials

 BIOCON    NOVARTIS
EQUITY SHARE DATA
    BIOCON
Mar-18
NOVARTIS
Mar-18
BIOCON /
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,188758 156.7%   
Low Rs305579 52.7%   
Sales per share (Unadj.) Rs68.7228.4 30.1%  
Earnings per share (Unadj.) Rs7.631.7 23.8%  
Cash flow per share (Unadj.) Rs14.032.8 42.6%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.11.5 9.0%  
Book value per share (Unadj.) Rs86.3297.1 29.1%  
Shares outstanding (eoy) m600.0024.69 2,430.1%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.9 371.1%   
Avg P/E ratio x98.921.1 469.3%  
P/CF ratio (eoy) x53.420.4 261.9%  
Price / Book Value ratio x8.62.2 384.3%  
Dividend payout %13.231.5 42.0%   
Avg Mkt Cap Rs m447,90016,505 2,713.7%   
No. of employees `0006.10.7 920.5%   
Total wages/salary Rs m9,3111,445 644.2%   
Avg. sales/employee Rs Th6,705.88,441.3 79.4%   
Avg. wages/employee Rs Th1,514.22,163.6 70.0%   
Avg. net profit/employee Rs Th736.91,173.1 62.8%   
INCOME DATA
Net Sales Rs m41,2345,639 731.3%  
Other income Rs m2,0621,718 120.0%   
Total revenues Rs m43,2967,357 588.5%   
Gross profit Rs m8,291-63 -13,265.6%  
Depreciation Rs m3,85125 15,221.3%   
Interest Rs m61555 1,112.1%   
Profit before tax Rs m5,8871,575 373.7%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569792 198.2%   
Profit after tax Rs m4,531784 578.2%  
Gross profit margin %20.1-1.1 -1,814.1%  
Effective tax rate %26.750.3 53.0%   
Net profit margin %11.013.9 79.1%  
BALANCE SHEET DATA
Current assets Rs m41,4869,522 435.7%   
Current liabilities Rs m21,4133,296 649.7%   
Net working cap to sales %48.7110.4 44.1%  
Current ratio x1.92.9 67.1%  
Inventory Days Days6437 174.7%  
Debtors Days Days9428 331.3%  
Net fixed assets Rs m50,66146 110,132.6%   
Share capital Rs m3,000123 2,431.1%   
"Free" reserves Rs m48,8087,213 676.7%   
Net worth Rs m51,8087,336 706.2%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89711,105 899.6%  
Interest coverage x10.629.5 35.9%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.5 81.3%   
Return on assets %5.27.6 68.2%  
Return on equity %8.710.7 81.9%  
Return on capital %9.622.2 43.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05861 19,897.7%   
Fx outflow Rs m7,3483,630 202.4%   
Net fx Rs m4,710-3,570 -131.9%   
CASH FLOW
From Operations Rs m6,6211,610 411.3%  
From Investments Rs m-6,840687 -995.6%  
From Financial Activity Rs m-2,397-2,677 89.6%  
Net Cashflow Rs m-2,612-380 688.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 2.0 420.0%  
FIIs % 10.7 1.6 668.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 21.5 92.6%  
Shareholders   109,995 41,647 264.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Crude Oil Prices, Developments in the Automobile Sector, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended their trading session on a strong note yesterday. Gains were largely seen in the oil & gas sector and telecom sector.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 24, 2019 (Close)

TRACK BIOCON

BIOCON - IPCA LABS COMPARISON

COMPARE BIOCON WITH

MARKET STATS